DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Cowden syndrome 6 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCowden syndrome 6 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cowden syndrome 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
AKT serine/threonine kinase 1 (AKT1) — AKT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet propanoylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7NH5 · 1.9 Å · ligand ~{N}-methyl-6-[4-[[4-[2-oxidanylidene-6-(propanoylamino)-3~{H}-benzimidazol-1-yl]piperidin-1-yl]methyl]phenyl]-5-phenyl-pyridine-3-carboxamide (UC8). Experimental structure, not a prediction.
What the evidence adds up to
A 34-year-old man presented with Lhermitte-Duclos disease and was subsequently found to have macrocephaly, thyroid nodules and gastrointestinal polyps, consistent with Cowden syndrome. A separate report describes a 46-year-old woman with typical clinical features of Cowden syndrome in whom DNA sequencing revealed a novel heterozygous mutation (c.403A > G, p.Ile135Val) in exon 5 of the PTEN gene, a mutation not previously reported in the condition. Cowden syndrome is an autosomal dominant disorder characterised by multiple hamartomas and macrocephaly, with the PTEN gene as the responsible locus; PTEN negatively regulates cell proliferation and survival.
One abstract argues that because Cowden syndrome involves abnormal development of all three germ layers, and because mesenchymal tissue gives rise to the vascular system, cerebral blood vessel pathology can occur in conjunction with the disease and cause cerebrovascular disease. No patient numbers, stroke rates, or survival data are provided in that report.
No drug, no treatment, no intervention of any kind is mentioned in any of these three abstracts. There is no evidence of any clinical trial, no response rate, no survival benefit, and no suggestion of repurposing. What is missing is any study that tests a drug in Cowden syndrome patients, any trial design, any patient stratification by PTEN mutation type, and any funding for such work.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Neurosurgery · 2005 · 7 citations
Cowden's syndrome with Lhermitte–Duclos disease
AbstractCowden's syndrome (CS) is a rare autosomal dominant condition featuring multiple hamartomas, often with mucocutaneous lesions, goitre, breast cancer, gastrointestinal polyps or even Lhermitte-Duclos disease (LDD). In this article we report the case of a 34-year-old man who was diagnosed with LDD. Subsequent examinations also revealed manifestations of CS, i.e. macrocephaly, thyroid nodules and gastrointestinal polyps.
The Journal of Medical Investigation · 2020 · 2 citations · open access
A case of Cowden syndrome with a novel mutation in the PTEN gene
AbstractCowden syndrome (CS) is an autosomal dominant inherited disorder characterized by macrocephaly and multiple hamartomas. The responsible gene is PTEN (phosphate and tensin homolog detected on chromosome 10), which negatively regulates cell proliferation and survival. We herein present a 46-year-old woman with the typical clinical features of CS. A DNA sequencing analysis of the coding regions and flanking introns of the PTEN gene revealed a novel heterozygous mutation (c.403A > G, p.Ile135Val) in exon 5 that had not been previously reported in CS. J. Med. Invest. 67 : 200-201, February, 2020.
Bulletin of Siberian Medicine · 2016 · 1 citations · open access
Cowden syndrome is a risk factor for ischemic stroke
AbstractCowden syndrome is a rare genetic disorder caused by the abnormal development of all three germ layers. Taking into consideration the mesodermal origin of mesenchymal tissue that gives rise to the vascular system, the pathology of cerebral blood vessels can occur in conjunction with this disease and cause the development of cerebrovascular disease in such patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
